enzastaurin has been researched along with deoxycytidine in 7 studies
| Studies (enzastaurin) | Trials (enzastaurin) | Recent Studies (post-2010) (enzastaurin) | Studies (deoxycytidine) | Trials (deoxycytidine) | Recent Studies (post-2010) (deoxycytidine) |
|---|---|---|---|---|---|
| 188 | 52 | 99 | 18,160 | 4,652 | 8,898 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alice Miller, M; Pearce, HL | 1 |
| Basche, M; Britten, CD; Carducci, M; Cook, CA; Eckhardt, SG; Green, LJ; Herbst, RS; Jaken, S; Marder, P; Musib, LC; Ray, C; Thornton, D | 1 |
| Beerepoot, LV; Beijnen, JH; Enas, N; Mehra, N; Musib, L; Radema, SA; Rademaker-Lakhai, JM; Schellens, JH; van Hal, G; van Maanen, R; Vermaat, JS; Visseren-Grul, CM; Voest, EE; Witteveen, EO | 1 |
| Baldwin, J; Basche, M; Britten, CD; Camidge, DR; Darstein, C; Finn, RS; Gail Eckhardt, S; Gore, L; Holden, SN; Leong, S; Musib, L; O'Bryant, CL; Thornton, D | 1 |
| Jian, W; Lerner, SP; Levitt, JM; Sonpavde, G; Yamashita, H | 1 |
| Asmar, L; Becerra, C; Boehm, KA; Gersh, RH; Gill, JF; Hozak, RR; Kuefler, PR; Mullaney, BP; Myrand, SP; Nicol, SJ; Obasaju, CK; Richards, DA; Wilfong, LS; Zhan, F; Zhao, L | 1 |
| Abdulnabi, R; Clemons, M; Gelmon, K; Iscoe, N; Jordaan, JP; Joy, AA; Kotliar, M; Lynch, J | 1 |
4 trial(s) available for enzastaurin and deoxycytidine
| Article | Year |
|---|---|
Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C beta-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer.
Topics: AC133 Antigen; Adult; Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; CD146 Antigen; Cisplatin; Deoxycytidine; Endothelium, Vascular; Female; Gemcitabine; Glycoproteins; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms; Peptides; Prognosis; Protein Kinase C; Protein Kinase C beta; RNA, Messenger; Survival Rate | 2007 |
A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Female; Floxuridine; Fluorouracil; Follow-Up Studies; Humans; Indoles; Male; Middle Aged; Monocytes; Neoplasms; Phosphorylation; Protein Kinase C; Protein Kinase C beta | 2008 |
Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: results of a phase II, randomized, noncomparative study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Immunohistochemistry; Indoles; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Quality of Life; Treatment Outcome | 2011 |
Phase II, double-blind, randomized trial of capecitabine plus enzastaurin versus capecitabine plus placebo in patients with metastatic or recurrent breast cancer after prior anthracycline and taxane therapy.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Argentina; Australia; Breast Neoplasms; Canada; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Early Termination of Clinical Trials; Female; Fluorouracil; Humans; Indoles; Kaplan-Meier Estimate; Mexico; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Placebo Effect; Proportional Hazards Models; Risk Assessment; Risk Factors; South Africa; Taxoids; Time Factors; Treatment Outcome | 2010 |
3 other study(ies) available for enzastaurin and deoxycytidine
| Article | Year |
|---|---|
The evolution of cancer research and drug discovery at Lilly Research Laboratories.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Deoxycytidine; Drug Industry; Gemcitabine; Glutamates; Guanine; History, 20th Century; Humans; Indoles; Neoplasms; Pemetrexed; United States | 2005 |
Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-beta inhibitor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Capecitabine; Cell Line, Tumor; Clinical Trials, Phase I as Topic; Deoxycytidine; Enzyme Activators; Enzyme Inhibitors; Flow Cytometry; Fluorouracil; Follow-Up Studies; Humans; Indoles; Leukocytes, Mononuclear; Monocytes; Neoplasms; Protein Kinase C; Protein Kinase C beta; Reproducibility of Results; Sensitivity and Specificity; Signal Transduction; Structure-Activity Relationship; Treatment Outcome | 2006 |
Enzastaurin shows preclinical antitumor activity against human transitional cell carcinoma and enhances the activity of gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Immunoenzyme Techniques; Indoles; Mice; Mice, Nude; Protein Kinase C; Protein Kinase C beta; Proto-Oncogene Proteins c-akt; Ribonucleotide Reductases | 2009 |